G92.01
Immune effector cell-associated neurotoxicity syndrome, grade 1
Clinical Classification Guidelines
Inclusion Terms
- ICANS, grade 1
Medical Intelligence & Overview
Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) is a potential complication that can occur after treatments involving immune effector cells, such as CAR T-cell therapy. Grade 1 indicates mild symptoms. Recognizing this condition early is important for managing it effectively and ensuring patient safety. This guide provides an overview of ICANS grade 1, covering causes, symptoms, diagnosis, and treatment options to help patients and caregivers understand this condition better.
Causes & Symptoms
Clinical Causes: Administration of immune effector cell therapies such as CAR T-cell therapy Immune system activation leading to brain inflammation Cytokine release syndrome interacting with neurotoxicity Individual variations in immune response to treatment
Key Symptoms: Mild confusion or difficulty concentrating Transient headache L difficulty with speech or understanding language Mild tremors or abnormal movements Mild weakness or numbness in limbs Altered mental state that is not severe
Diagnostic & Treatment
Diagnosis Path: Diagnosis of grade 1 ICANS involves a comprehensive neurological assessment. Healthcare professionals evaluate neurological symptoms, conduct physical and cognitive examinations, and may perform imaging studies such as MRI to rule out other causes. Blood tests measuring cytokine levels can support diagnosis, especially in the context of recent immunotherapy. It's important to distinguish ICANS from other neurological conditions for appropriate management.
Treatment Protocols: Management of grade 1 ICANS focuses on monitoring and supportive care. Typically, healthcare providers will observe symptoms closely and may recommend interventions such as:
Clinical Advice & FAQs
Billing Guidance
Is G92.01 a billable ICD-10 code?
Yes, G92.01 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report G92.01?
Clinical documentation must specify the nature of Immune effector cell-associated neurotoxicity syndrome, grade 1 and any associated comorbidities for accurate reporting.
Cite this Clinical Reference